Under the terms of the collaboration, which is supported by a grant from the Middle Kingdom United Development Midlands, London Astrimmune Genetics and prepare a proposal for the identification of biomarkers predictive of clinical response. London Genetics seven academic partners who have an annual budget of more than GBP650m of research, are able to provide expertise in areas such as biopsy specimens and animal models of cancer, as well as experience in the genetics of the immune response to cancer vaccines.Candidate vaccine induced antibody production against Astrimmune gastrin, a hormone that is known to stimulate the growth of many types of gastrointestinal cancer. Because the differential response rates were observed in clinical trials of other gastrin block, with some patients respond very well and others just there is a clear need for biomarkers to help identify patients most likely to benefit from products Astrimmune. For example, there is the possibility that the variable response rates may be due in part to the inclusion of some patients with tumors that do not respond gastrin, or those who have not been able to respond immunologically.
London Genetics Limited, an expert in the use of pharmacogenetics in drug discovery and clinical development, and Astrimmune, focusing on gastrointestinal, are pleased to announce it has entered into a collaboration to design a program to identify biomarkers. The plan Astrimmune vaccine candidates at an early stage, will be used in applications for additional funding for its development. Financial terms were not disclosed.
Dominique Kleyn, CEO of London Genetics, said: “This partnership is an important pharmacogenetic development opportunities, and we are delighted to work with Astrimmune on this important project. As evidenced by our recent collaboration with Diaceutics and increasingly recognized by the biopharmaceutical industry, pharmacogenetics, biomarkers, and the stratification of patients become an important part of drug discovery and development process. London genetic network of over 3000 academic groups makes it an ideal partner for pharmaceutical and biotechnology companies in this work. ”
Fred Jacobs, Managing Director of Astrimmune, said: “Pancreatic cancer is an area of serious unmet medical needs, with a five-year survival rate of about 5% and few treatment options. Availability of a biomarker to select patients most likely to benefit from Astrimmune candidate vaccine can be expected to accelerate the development of this product and increase its chances of reaching the market in the future. London Genetics is an expert in this field and Astrimmune is pleased to work with ‘company on this important part of project development. “